Invitrogen last week issued its fourth-quarter and full-year financial report for 2004, and restated its 2003 earnings calculations to comply with new accounting standards for public companies to report the potentially dilutitive effect of contingently convertible debt on earnings.

"It's a what-if analysis, showing what could happen," Steven Huddart, an accounting professor at Pennsylvania State University, told BioCommerce Week.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Lawmakers have asked four direct-to-consumer genetic testing companies to explain their privacy policies and security measures, according to Stat News.

The Trump Administration has proposed a plan to reorganize the federal government, the Washington Post reports.

In Science this week: genetic overlap among many psychiatric disorders, and more.

The Economist writes that an increasing number of scientific journals don't do peer review.